EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Tyrosyl-tRNA sequestration triggers tyrosyl-tRNA synthetase-associated peripheral neuropathy

Moushami Mallik, Abigail L D Tadenev, Natalia Mora, Vanessa Lewandowski, Daniel Köster, María Landínez-Macías, Robin Thompson, María P Menafra, Noah K Taylor, Pascal van Lith, Nick van Bakel, Marica Catinozzi, Scott Q Harper, Zoya Ignatova, Robert W Burgess, Erik Storkebaum

Brain · 2026-11-04 · 149 (11) · 4052-4065

DOI: 10.1093/brain/awag204 ↗
AbstractBibliografische Angaben

Abstract

Abstract Mono-allelic mutations in seven cytosolic aminoacyl-tRNA synthetase genes cause Charcot–Marie–Tooth (CMT) peripheral neuropathy. Here, we report that tyrosyl-tRNA (tRNATyr) sequestration by CMT-mutant tyrosyl-tRNA synthetase (TyrRS) is the molecular root cause of CMT-YARS1. tRNATyr sequestration depletes the cellular free tRNATyr pool, leading to insufficient tyrosyl-tRNATyr production and ribosome stalling at tyrosine codons. In three Drosophila CMT-YARS1 models, transgenic overexpression of tRNATyr rescued peripheral neuropathy phenotypes and defective mRNA translation. We provide biochemical evidence for tRNATyr sequestration by the three CMT-TyrRS variants expressed in the Drosophila models and ribosome profiling revealed selective ribosome pausing at the two tyrosine codons. In the Yars1E196K mouse model, adeno-associated virus serotype 9 (AAV9)-mediated overexpression of tRNATyr—but not wild-type TyrRS protein—fully rescued motor performance deficits, reduced nerve conduction velocity and reduced motor axon calibre. Furthermore, AAV9-tRNATyr gene therapy prevented activation of the integrated stress response in spinal motor neurons, indicating resolution of ribosome stalling. Thus, elevating tRNATyr levels constitutes a novel therapeutic approach for CMT-YARS1.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →